CEPI’s crucial work to develop safe and effective vaccines against COVID-19 has received further financial support from The Government of Canada.
Canada, a long-standing investor in CEPI, announced today that it will contribute additional financial support for CEPI’s vital COVID-19 R&D efforts, as part of a wider investment in the WHO’s Access to COVID-19 Tools (ACT) Accelerator.
In September, Canada made substantial commitments to ensuring equitable access to COVID-19 vaccines through COVAX—the vaccines pillar of the ACT Accelerator—which is co-led by CEPI, GAVI, and WHO. COVAX aims to ensure equitable access to COVID-19 vaccines and end the acute phase of the pandemic by the end of 2021.
Chief Executive Officer, CEPI
Karina Gould’s (Canada’s Minister of International Development) announcement that Canada will contribute a further C$255 million (US$200 million) in support of the ACT Accelerator further cements Canada’s international commitment to globally fair allocation to COVID-19 vaccines and other life-saving-interventions.
Minister of International Development, Canada
Image credit: Adam Scotti (PMO)